+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Opioid Agonist"

From
From
Opioid Withdrawal Syndrome- - Pipeline Insight, 2024 - Product Thumbnail Image

Opioid Withdrawal Syndrome- - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Opioid Receptor Agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Opioid Receptor Agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Opioid kappa receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Opioid kappa receptor agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Opioid mu receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Opioid mu receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
  • 9 Results (Page 1 of 1)
Loading Indicator

The Opioid Agonist market is a subset of the Addiction Disorders Drugs market, which focuses on medications used to treat opioid addiction. These drugs are designed to reduce cravings and withdrawal symptoms, and to block the effects of other opioids. Commonly prescribed opioid agonists include methadone, buprenorphine, and naltrexone. These medications are used in combination with counseling and other forms of therapy to help individuals with opioid addiction achieve long-term recovery. Opioid agonists are available in both generic and brand-name formulations. They are typically prescribed by a physician or other healthcare provider, and are available through pharmacies and other retail outlets. Some companies in the Opioid Agonist market include Reckitt Benckiser, Purdue Pharma, Mallinckrodt Pharmaceuticals, and Mylan. Show Less Read more